{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:40:17Z","timestamp":1789094417918,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.cll.2004.05.003","type":"journal-article","created":{"date-parts":[[2005,4,13]],"date-time":"2005-04-13T17:01:38Z","timestamp":1113411698000},"page":"721-735","source":"Crossref","is-referenced-by-count":32,"title":["Emerging fungal resistance"],"prefix":"10.1016","volume":"24","author":[{"given":"John W.","family":"Baddley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2004.05.003_BIB1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","article-title":"Trends in postmortem epidemiology of invasive fungal infections at a university hospital","volume":"33","author":"Groll","year":"1996","journal-title":"J Infect"},{"key":"10.1016\/j.cll.2004.05.003_BIB2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.cll.2004.05.003_BIB3","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/JCM.40.10.3551-3557.2002","article-title":"Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2004.05.003_BIB4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1470-9465.2004.00839.x","article-title":"Infections due to emerging and uncommon medically important fungal pathogens","volume":"10","author":"Walsh","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cll.2004.05.003_BIB5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/375822","article-title":"Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi","volume":"37","author":"Husain","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1086\/344058","article-title":"Antifungal resistance in pathogenic fungi","volume":"35","author":"Perea","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.cll.2004.05.003_BIB7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/43.1.149","article-title":"Comparative in-vitro activity of voriconazole (UK 109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum","volume":"43","author":"Cuenca-Estrella","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(02)08162-X","article-title":"Antifungal drug resistance of pathogenic fungi","volume":"359","author":"Kontoyianis","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cll.2004.05.003_BIB9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1128\/AAC.43.4.836","article-title":"High-frequency in vitro switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance","volume":"43","author":"Yoon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.11.2.382","article-title":"Clinical, cellular, and molecular factors that contribute to antifungal drug resistance","volume":"11","author":"White","year":"1998","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2004.05.003_BIB11","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1086\/344658","article-title":"Antifungal drug resistance","volume":"36","author":"Loeffler","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB12","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard\u20142nd edition","author":"National Committee for Clinical Laboratory Standards","year":"2002"},{"key":"10.1016\/j.cll.2004.05.003_BIB13","series-title":"Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved Standard\u20141st edition","author":"National Committee for Clinical Laboratory Standards","year":"2002"},{"issue":"2","key":"10.1016\/j.cll.2004.05.003_BIB14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/24.2.235","article-title":"Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro\u2013in vivo correlation data for fluconazole, itraconazole, and Candida infections","volume":"24","author":"Rex","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of actions, mechanism of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cll.2004.05.003_BIB17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10408418709104448","article-title":"Anti-Candida drugs\u2014the biochemical basis for their activity","volume":"15","author":"Vanden Bossche","year":"1978","journal-title":"CRC Crit Rev Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB18","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/JCM.28.7.1616-1622.1990","article-title":"Trichosporon beigelii [asahii]: an emerging pathogen resistant to amphotericin B","volume":"28","author":"Walsh","year":"1990","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2004.05.003_BIB19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.cll.2004.05.003_BIB20","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/AAC.47.9.2717-2724.2003","article-title":"Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae","volume":"47","author":"Young","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.cll.2004.05.003_BIB21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1128\/AAC.46.2.531-533.2002","article-title":"Sterol and fatty acid composition of Candida lusitaniae clinical isolates","volume":"46","author":"Peyron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1348-0421.1999.tb01231.x","article-title":"Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus","volume":"43","author":"Seo","year":"1999","journal-title":"Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.cll.2004.05.003_BIB23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","article-title":"Oral azole drugs as systemic antifungal therapy","volume":"330","author":"Como","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cll.2004.05.003_BIB24","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.46.6.1704-1713.2002","article-title":"Resistance mechanisms in clinical isolates of Candida albicans","volume":"46","author":"White","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.cll.2004.05.003_BIB25","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1128\/AAC.47.8.2424-2437.2003","article-title":"Molecular mechanisms of itraconazole resistance in Candida dubliniensis","volume":"47","author":"Pinjon","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB26","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1128\/AAC.44.6.1578-1584.2000","article-title":"Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750","volume":"44","author":"Barchiesi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2958.2003.03281.x","article-title":"Identification and characterization of a Cryptococcus neoformans ATP Binding Cassette (ABC) transporter-encoding gene, CnDR1, involved in the resistance to fluconazole","volume":"47","author":"Posteraro","year":"2003","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1087-1845(02)00016-6","article-title":"Induced expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in response to itraconazole","volume":"36","author":"Slaven","year":"2002","journal-title":"Fungal Genet Biol"},{"key":"10.1016\/j.cll.2004.05.003_BIB29","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/AAC.39.11.2378","article-title":"Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters","volume":"39","author":"Sanglard","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB30","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1128\/AAC.41.7.1482","article-title":"Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus","volume":"41","author":"White","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1042\/bst0180056","article-title":"Mutation in cytochrome P450-dependent 14\u03b1-demethylase results in decreased affinity for azole antifungals","volume":"28","author":"Vanden Bossche","year":"1990","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.cll.2004.05.003_BIB32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0014-5793(95)00684-2","article-title":"Resistant P450A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients","volume":"368","author":"Lamb","year":"1995","journal-title":"FEBS Lett"},{"issue":"10","key":"10.1016\/j.cll.2004.05.003_BIB33","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1128\/AAC.42.10.2645","article-title":"Mechanism of fluconazole resistance in Candida krusei","volume":"42","author":"Orozco","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/AAC.42.2.241","article-title":"Amino acid substitutions in the cytochrome P-450 lanosterol 14\u03b1-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents","volume":"42","author":"Sanglard","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB35","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/infdis\/168.5.1311","article-title":"Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice","volume":"168","author":"Karyotakis","year":"1993","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.cll.2004.05.003_BIB36","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/AAC.47.9.2717-2724.2003","article-title":"Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae","volume":"47","author":"Young","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.6.1.1","article-title":"Compounds active against cell walls of medically important fungi","volume":"6","author":"Hector","year":"1993","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cll.2004.05.003_BIB38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/375080","article-title":"Caspofungin","volume":"36","author":"Deresinski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.mi.48.100194.002351","article-title":"Antibiotics that inhibit fungal cell wall development","volume":"48","author":"De Bono","year":"1994","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB40","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/AAC.41.7.1612","article-title":"In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species","volume":"41","author":"Vasquez","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2004.05.003_BIB41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/mmy.39.1.55.66","article-title":"Fungal beta (1,3)-D-glucan synthesis","volume":"39","author":"Douglas","year":"2001","journal-title":"Med Mycol"},{"issue":"26","key":"10.1016\/j.cll.2004.05.003_BIB42","doi-asserted-by":"crossref","first-page":"12907","DOI":"10.1073\/pnas.91.26.12907","article-title":"The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase","volume":"91","author":"Douglas","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.cll.2004.05.003_BIB43","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1128\/jb.176.18.5686-5696.1994","article-title":"A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase","volume":"176","author":"Douglas","year":"1994","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.cll.2004.05.003_BIB44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/jm00028a003","article-title":"Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives","volume":"37","author":"Bouffard","year":"1994","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.cll.2004.05.003_BIB45","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.41.11.2471","article-title":"Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors","volume":"41","author":"Douglas","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.cll.2004.05.003_BIB46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2958.2003.03430.x","article-title":"The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin","volume":"48","author":"Schuetzer-Muehlbauer","year":"2003","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB47","first-page":"113","article-title":"Mode of action of 5-fluorocytosine in the treatment of cryptococcal and candida mycoses","volume":"21","author":"Polak","year":"1975","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cll.2004.05.003_BIB48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.7326\/0003-4819-74-4-535","article-title":"5-fluorocytosine in the treatment of cryptococcal and candida mycoses","volume":"74","author":"Fass","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cll.2004.05.003_BIB49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity, and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB50","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0006-2952(78)90507-5","article-title":"Mode of action of 5-fluorocytosine","volume":"27","author":"Diasio","year":"1978","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2004.05.003_BIB51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02681219480000821","article-title":"Mechanisms and clinical impact of antifungal drug resistance","volume":"32","author":"Vanden Bossche","year":"1994","journal-title":"J Med Vet Mycol"},{"key":"10.1016\/j.cll.2004.05.003_BIB52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1749-6632.1988.tb40411.x","article-title":"Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species","volume":"544","author":"Fasoli","year":"1988","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cll.2004.05.003_BIB53","first-page":"158","article-title":"5-fluorocytosine\u2014current status with special references to mode of action and drug resistance","volume":"4","author":"Polak","year":"1977","journal-title":"Contrib Microbiol Immunol"},{"key":"10.1016\/j.cll.2004.05.003_BIB54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/AAC.2.3.114","article-title":"In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata","volume":"2","author":"Normark","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000221854","article-title":"Mode of action of 5-fluorocytosine and mechanisms of resistance","volume":"21","author":"Polak","year":"1975","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.cll.2004.05.003_BIB56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/520194","article-title":"National epidemiology of mycoses survey (NEMIS): variations in rates of blood stream infections due to Candida species in seven surgical intensive care units","volume":"29","author":"Rangel-Frausto","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/520192","article-title":"Nosocomial bloodstream infections in United States hospitals: a three-year analysis","volume":"29","author":"Edmond","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cll.2004.05.003_BIB58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/321811","article-title":"Risk factors for candidal blood stream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study","volume":"33","author":"Blumberg","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.cll.2004.05.003_BIB59","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1128\/JCM.41.5.2176-2179.2003","article-title":"Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location","volume":"41","author":"Pfaller","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2004.05.003_BIB60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1470-9465.2004.t01-1-00844.x","article-title":"Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida","volume":"10","author":"Pfaller","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.cll.2004.05.003_BIB61","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1128\/JCM.41.5.1833-1837.2003","article-title":"Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus\u2013seropositive children and adults in a long-term care facility","volume":"41","author":"Makarova","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB62","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cll.2004.05.003_BIB63","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2004.05.003_BIB64","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1093\/clinids\/17.Supplement_2.S507","article-title":"Management of cryptococcosis","volume":"17","author":"Dismukes","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB65","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1128\/AAC.45.11.3065-3069.2001","article-title":"Trends in antifungal drug susceptibility in Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998","volume":"45","author":"Brandt","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1054\/drup.1999.0090","article-title":"Drug resistance in Cryptococcus neoformans","volume":"2","author":"Perfect","year":"1999","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.cll.2004.05.003_BIB67","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/clinids\/22.2.322","article-title":"Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing","volume":"22","author":"Witt","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB68","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/clinids\/23.6.1337-a","article-title":"Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis","volume":"23","author":"Armengou","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB69","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/AAC.44.6.1544-1548.2000","article-title":"Correlation of fluconazole MICs with clinical outcome in cryptococcal infection","volume":"44","author":"Aller","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/infdis\/166.1.121","article-title":"Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis","volume":"166","author":"Walsh","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB71","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine"},{"key":"10.1016\/j.cll.2004.05.003_BIB72","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/jinf.2000.0747","article-title":"Antifungal drug resistance in Aspergillus","volume":"41","author":"Moore","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.cll.2004.05.003_BIB74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jac\/40.3.401","article-title":"Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection","volume":"40","author":"Denning","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB75","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1128\/JCM.37.12.3946-3951.1999","article-title":"Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species","volume":"37","author":"Arikan","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.cll.2004.05.003_BIB76","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JCM.37.7.2343-2345.1999","article-title":"In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison with voriconazole","volume":"37","author":"Sutton","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB77","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1128\/JCM.41.12.5525-5529.2003","article-title":"Epidemiology of Aspergillus terreus at a university hospital","volume":"41","author":"Baddley","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB78","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1086\/520297","article-title":"Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature","volume":"26","author":"Iwen","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB79","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/clinids\/16.1.118","article-title":"Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts","volume":"16","author":"Tritz","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB80","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1099\/0022-1317-49-7-601","article-title":"Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis","volume":"49","author":"Dannaoui","year":"2000","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB81","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jac\/44.4.553","article-title":"In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole","volume":"44","author":"Dannaoui","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.cll.2004.05.003_BIB82","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/47.3.333","article-title":"Acquired itraconazole resistance in Aspergillus fumigatus","volume":"47","author":"Dannaoui","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB83","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1056\/NEJM200212263472618","article-title":"Multidrug resistance in Aspergillus fumigatus","volume":"26","author":"Warrius","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cll.2004.05.003_BIB84","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1099\/00222615-48-12-1087","article-title":"In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus","volume":"48","author":"Dannaoui","year":"1999","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.cll.2004.05.003_BIB85","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/AAC.46.2.556-557.2002","article-title":"Azole cross-resistance in Aspergillus fumigatus","volume":"46","author":"Mosquera","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/46.2.229","article-title":"A comparative study of the in-vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCG 56592)","volume":"46","author":"Manavathu","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.cll.2004.05.003_BIB87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00005792-198803000-00001","article-title":"The emerging role of Fusarium infections in patients with cancer","volume":"67","author":"Anaissie","year":"1988","journal-title":"Medicine"},{"key":"10.1016\/j.cll.2004.05.003_BIB88","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V90.3.999","article-title":"Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management","volume":"90","author":"Boutati","year":"1997","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2004.05.003_BIB89","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1093\/clinids\/17.Supplement_2.S487","article-title":"Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management","volume":"17","author":"Vartivarian","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB90","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","article-title":"In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cll.2004.05.003_BIB91","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/infdis\/165.6.1155","article-title":"Lack of activity of amphotericin B in systemic murine fusarial infection","volume":"165","author":"Anaissie","year":"1992","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.cll.2004.05.003_BIB92","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2004.05.003_BIB93","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/375842","article-title":"Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient","volume":"37","author":"Consigny","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cll.2004.05.003_BIB94","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of in-vitro activities of new triazole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.cll.2004.05.003_BIB95","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1086\/338636","article-title":"Disseminated phaeohyphomycosis: review of an emerging mycosis","volume":"34","author":"Revankar","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.cll.2004.05.003_BIB96","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1128\/AAC.39.6.1361","article-title":"Activity of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii","volume":"39","author":"Walsh","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.cll.2004.05.003_BIB97","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271204000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271204000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T20:42:11Z","timestamp":1586205731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271204000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0272271204000599"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2004.05.003","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}